![Yüksel Ürün: US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer](https://oncodaily.com/pub/uploads/2024/01/FDA.jpeg)
Mar 28, 2024, 03:11
Yüksel Ürün: US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer
Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared a post on X:
“US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer!”
View additional information.
Source: Yüksel Ürün/X
Aug 13, 2024, 01:52